Skip to content

Author

F. Ou

We have 3 of 249 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.

Endocytosis regulates receptor trafficking and signaling, yet its role in colorectal cancer (CRC) remains unclear. We analyzed transcriptomic data from 15,025 CRC tumors to evaluate gene expression in clathrin-mediated endocytosis (CME) and the endosomal sorting complexes required for transport (ESCRT) pathway. Pathway...

H. Arai, A. Elliott, Yan Yang et al. · 0 citations
Open access Aug 2026

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.

Nguyen H. Tran, M. Palmer, Angela Ulrich et al. · 0 citations
Open access Aug 2026

Addition of High-Dose Vitamin D3 to Standard Treatment in Patients with Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703)

High-dose vitamin D3 added to standard treatment improved progression-free survival (PFS) compared to standard-dose vitamin D3 in patients with metastatic colorectal cancer (mCRC) in a phase 2 randomized clinical trial.

K. Ng, F. Ou, T. Zemla et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.